NLV Partners was formed in 2005, when the healthcare team spun out from the Sprout Group, the venture capital affiliate of Credit Suisse. The NLV team has been built over more than 18 years and has managed the health care technology portfolios in four Sprout funds as well as in two NLV funds:

  • New Leaf Ventures I, L.P., a $310 million fund that closed in 2005

  • New Leaf Ventures II, L.P., a $450 million fund that closed in late 2007 and began its new investment cycle in 2008

The team’s investments have spanned a range of opportunities, across stages and transaction types. Some representative investments include the following:

Start Ups: Afferent Pharmaceuticals, CalChan Pharmaceuticals, Durata Therapeutics (NASD: DRTX), Ilypsa (Amgen), Interlace Medical (Hologic), NxStage Medical (NASD: NXTM), and Relypsa (NASD: RLYP)

Private Financings: Auxilium (NASD: AUXL), Aspreva Pharmaceuticals (Galenica Group), Chimerix (NASD: CMRX), Cerexa (Forest Laboratories), ePocrates (athenahealth), Epicor Medical (St. Jude), iRhythm Technologies, Oriel Therapeutics (Novartis-Sandoz Div.), Oxford Immunotec (NASD: OXFD), Pearl Therapeutics (Astra-Zeneca), Phase Forward (Oracle), Sapient Health Networks (WebMD), Stromedix (Biogen Idec), and Visiogen (Abbott)

PIPEs: Acadia Pharmaceuticals (NASD: ACAD), Array BioPharma (NASD: ARRY), and MEI Pharma (NASD: MEIP)

Restructurings/Recaps/Structured Financings: Cephalon (NASD: CEPH) , Intarcia Therapeutics, ISTA Pharmaceuticals (Baush+Lomb), Sirna Therapeutics (Merck) and Synageva BioPharma (NASD: GEVA)

Buyouts: Charles River Laboratories, Focus Diagnostics (Quest Diagnostics), and Nycomed (Takeda Pharmaceuticals)

Both NLV-I and NLV-II are capitalized by commitments from highly respected limited partners, many of whom have invested with the New Leaf team over multiple funds. These limited partners include a mix of large corporate and public sector pension funds, funds of funds, endowments, and other private investors.

* Company in parentheses and italics denotes acquiring company